Add-on deep transcranial magnetic stimulation (dTMS) in patients with dysthymic disorder comorbid with alcohol use disorder: A comparison with standard treatment.
Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. World J Biol Psychiatry. 2014 Aug 20:1-8.
The study compared standard drug treatment (n=10) with drug treatment combined with Brainsway® Deep TMS (Transcranial Magnetic Stimulation ; n=10) for treating mood and substance use disorders through stimulation of the Dorsolateral prefrontal cortex (DLPFC). The study, held over 6 months, included abstinent patients suffering from Alcohol Use Disorder, who also had a previous dysthymic disorder. The study showed that after 20 sessions of Deep TMS, craving and depressive symptoms dropped significantly, suggesting that Brainsway’s Deep TMS is well tolerated and effective as an add-on treatment for alcohol use disorder.
Brainsway's international website includes clinical and regulatory data for indications which were not cleared by the FDA for use in the United States.
This site is not intended for residents of the United States, its territories, and Puerto Rico.
The FDA cleared Brainsway's Deep TMS system for use in the U.S for treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.
Would you like to proceed to the international website? To proceed click here
or click here to close this window